Paeds SAQs · haematology-oncology-and-transfusion
Von Willebrand disease — formative SAQs
Formative SAQs on von Willebrand disease: the Sadler 1994 classification into type 1, the type 2 subtypes and type 3, the two functions of von Willebrand factor, the diagnostic panel and the exclusion of mild haemophilia A, the desmopressin response test, VWF concentrate and tranexamic acid, the management of heavy menstrual bleeding in adolescence, and the type-specific cautions including type 2B and type 3.
On this page
Study tools
Target exams
SAQ 1 (10 marks)
A fourteen-year-old girl is referred with heavy menstrual bleeding that has caused iron deficiency anaemia, easy bruising since childhood, and prolonged epistaxis. Her platelet count is 250 times ten to the nine per litre, her prothrombin time is normal, and her activated partial thromboplastin time is mildly prolonged. She is blood group O. [1]
- Give the most likely diagnosis and the initial investigations. (3) [2] [1]
- Classify the disease and explain the pathophysiology. (3) [5] [1]
- Outline the definitive management for this adolescent, including her heavy menstrual bleeding. (4) [4] [10]
Model answer — SAQ 1
(1) Diagnosis and investigations (3). The most likely diagnosis is von Willebrand disease, the most common inherited bleeding disorder. The combination of heavy menstrual bleeding severe enough to cause iron deficiency, lifelong easy bruising, prolonged epistaxis, a normal platelet count and a normal or mildly prolonged activated partial thromboplastin time is its classic presentation in an adolescent female. The initial investigations are the von Willebrand factor panel: von Willebrand factor antigen (quantity), von Willebrand factor activity measured as ristocetin cofactor activity or a newer glycoprotein Ib-binding assay (function), and factor VIII activity. Because she is blood group O, her von Willebrand factor level will be lower by about 25 to 30 percent, so a single normal result does not exclude the diagnosis and the panel is repeated on two or three occasions if needed. [1] [2]
(2) Classification and pathophysiology (3). Von Willebrand disease is classified by the Sadler 1994 system into type 1, a partial quantitative deficiency (about 75 to 80 percent of cases, usually autosomal dominant and mild); type 2, a qualitative defect with the subtypes 2A loss of high-molecular-weight multimers, 2B gain-of-function with thrombocytopenia, 2M normal multimers but reduced function, and 2N reduced factor VIII binding; and type 3, virtual absence of von Willebrand factor (severe, autosomal recessive, about 1 in a million). This girl's pattern is most consistent with type 1. Von Willebrand factor has two functions: it mediates platelet adhesion to the injured vessel wall by binding subendothelial collagen through its A3 domain and capturing platelets through their glycoprotein Ib receptor via its A1 domain, forming the primary platelet plug; and it carries and stabilises factor VIII through its D prime D3 domain, protecting it from proteolysis. A shortage therefore causes mucocutaneous bleeding and, when severe, a low factor VIII. [5] [4]
(3) Definitive management (4). The first step is to perform a desmopressin response test: desmopressin 0.3 micrograms per kg intravenously over 30 minutes, measuring von Willebrand factor activity and factor VIII at baseline and at 1 and 4 hours, with an adequate response defined as both reaching at least 0.50 IU per mL at peak, typically a 2 to 4 fold rise. For a responsive type 1 patient, desmopressin treats minor bleeds and covers minor procedures, with fluid restriction for 24 hours to avoid dilutional hyponatraemia. Her heavy menstrual bleeding is managed with non-replacement treatments: tranexamic acid 15 mg per kg orally three times daily during the period, a combined oral contraceptive pill or a levonorgestrel-releasing intrauterine device, and iron replacement for her iron deficiency anaemia. She is given a written bleed management plan, a medic alert device, advice to avoid aspirin and non-steroidal anti-inflammatory drugs, and enrolment in a comprehensive bleeding-disorder centre, with von Willebrand factor concentrate reserved for a non-response or for major surgery. [4] [10]
References9ShowHide
- [1]Leebeek FW, Eikenboom JC Von Willebrand's Disease. N Engl J Med, 2016.PMID 27959741
- [2]Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) expert panel report. Haemophilia, 2008.PMID 18315614
- [3]Castaman G, Goodeve A, Eikenboom J Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica, 2013.PMID 23633542
- [4]Mannucci PM Treatment of von Willebrand's Disease. N Engl J Med, 2004.PMID 15306670
- [5]Sadler JE A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost, 1994.PMID 8052974
- [7]Sadler JE Von Willebrand disease type 1: a diagnosis in search of a disease. Blood, 2003.PMID 12411289
- [8]Rodeghiero F, Tosetto A, Abshire T, Arnold DM, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost, 2010.PMID 20626619
- [10]Mannucci PM, Federici AB, James AH, Kessler CM von Willebrand disease in the 21st century: current approaches and new challenges. Haemophilia, 2009.PMID 19624761
- [12]Leebeek FWG, Peyvandi F, Escobar M, Tiede A, et al. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 trial results. Blood, 2022.PMID 35439298